NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lung cancer pill takes on chemo in major trial
Disease control Recruiting nowThis Phase 3 trial is testing a new oral drug called daraxonrasib (RMC-6236) against the standard chemotherapy docetaxel in about 590 people with advanced non-small cell lung cancer that has a specific RAS mutation. Participants must have already tried at least one prior treatmen…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New 'Smart Bomb' drug targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study is testing a new drug called ALX2004 in people with advanced lung, head and neck, esophageal, or colorectal cancers that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly t…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ODM-212 combined with other cancer treatments in people with advanced solid tumors, including mesothelioma, pancreatic cancer, and non-small cell lung cancer. The trial has two parts: first finding a safe dose, then checking how well it works. A…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for lung cancer: targeted drug BH-30643 enters human trials
Disease control Recruiting nowThis study tests a new drug, BH-30643, in adults with advanced non-small cell lung cancer that has certain gene changes (EGFR or HER2 mutations). The goal is to find a safe dose and see if the drug can shrink tumors. About 266 people will take part across multiple locations.
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: BlossomHill Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for advanced lung cancer: heat therapy plus drugs tested after first treatment fails
Disease control Recruiting nowThis study tests a new approach for people with advanced non-small cell lung cancer whose disease has worsened after initial immunotherapy and chemotherapy. Participants will receive a combination of microwave ablation (using heat to destroy tumors), the immunotherapy drug tislel…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo aims to shield bone marrow in tough lung cancer cases
Disease control Recruiting nowThis phase II trial tests whether giving trilaciclib before sacituzumab tirumotecan can protect bone marrow in patients with advanced EGFR-mutated non-small cell lung cancer that has stopped responding to standard treatments. About 49 participants will receive the drug combo and …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a pulsatile drug schedule beat brain metastases in lung cancer?
Disease control Recruiting nowThis trial is testing a higher, every-other-day dose of the drug furmonertinib in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). The study will compare this high-dose schedule …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: NA • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Poop pills may revive immunotherapy in lung cancer patients
Disease control Recruiting nowThis study tests whether taking a special fecal transplant (MaaT033) alongside an immunotherapy drug (Cemiplimab) can help overcome treatment resistance in advanced lung cancer patients who have taken antibiotics. Antibiotics can harm gut bacteria, which may make immunotherapy le…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Radiation plus drug cocktail shows promise for resistant lung cancer
Disease control Recruiting nowThis study tests whether adding precise radiation (SBRT) to a four-drug combination (sintilimab, bevacizumab, and chemotherapy) can help people with advanced EGFR-mutant lung cancer whose tumors have stopped responding to standard targeted therapy. About 53 participants will rece…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill shows promise against tough lung cancer mutations
Disease control Recruiting nowThis study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is t…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug cocktail aims to shrink tough cancers
Disease control Recruiting nowThis study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tide Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill hopes to tame tough lung cancer
Disease control Recruiting nowThis early-phase study tests a new tablet (HJ-004-02) in 36 adults with advanced non-squamous non-small cell lung cancer that has EGFR mutations. Participants must have tried other treatments without success or be unable to take them. The study checks safety, side effects, and ho…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Tongji University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New antibody cocktail shows promise in lung cancer trial
Disease control Recruiting nowThis Phase 2 trial tests whether adding a new drug called QL1706 (which targets two immune checkpoints) to standard chemotherapy can help people with advanced non-small cell lung cancer whose disease has progressed after initial immunotherapy. About 96 participants will receive e…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New antibody combo takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called ADU-1805, alone or combined with the immunotherapy Keytruda, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 130 pa…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Sairopa B.V. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new treatment called CEA-targeted CAR-T cells in people with advanced non-small cell lung cancer or breast cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack ca…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New study digs into long-term survival data for advanced lung cancer patients on immunotherapy
Knowledge-focused Recruiting nowThis study looks back at patients with advanced squamous non-small cell lung cancer who received tislelizumab combined with chemotherapy in a previous trial. Researchers want to see how long patients lived and find out who benefits most from this treatment. The goal is to better …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Italian study maps HER2 mutations in advanced lung cancer
Knowledge-focused Recruiting nowThis observational study will track 50 people with advanced non-small cell lung cancer (NSCLC) in Italy to see how common HER2 mutations are and how doctors currently treat them. Participants will be followed for one year. The goal is to understand real-world care, not to test a …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Lung cancer genes linked to dangerous blood clots in new study
Knowledge-focused Recruiting nowThis study looks at 500 people with advanced lung cancer to see if certain genetic changes (mutations) increase the risk of blood clots. Researchers will measure blood markers and track participants for 6 months. The goal is to learn which patients are at higher risk so doctors c…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: University Of Perugia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
AI-Powered scans could speed up lung cancer radiation treatment
Knowledge-focused Recruiting nowThis study looks at whether new AI tools can make adaptive radiotherapy—adjusting radiation plans during treatment—faster and easier for people with advanced lung cancer. Researchers will measure how long each step takes and compare plan quality using standard CT scans versus dai…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: NA • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC